

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 12934

Title: mTOR Inhibition in Hepatocellular Carcinoma

Reviewer code: 00069015

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-29 19:18

Date reviewed: 2014-08-09 09:15

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Y] Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> Existing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Existing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide with a poor prognosis and limited therapeutic approaches. This review emphasized mTOR signaling molecules for the potential efficacy in advanced HCC, in which it also provides a comprehensive depiction of the interaction between mTOR and clinical trials of phase III or II which demonstrates the pre-clinical relevance of the mTOR pathway in HCC pathogenesis and progression. The comments on the review is following: 1.As a english-writing paper in the peer-review journal, the paper displayed a well-written style in English. It is very eligible and understandable for the combination of context with figures in the paper. Especially, the figures 1-2 provided a comprehensive demonstration of mTOR signaling and relevant functions. 2.The mTOR pathway comprised of two main components, mTORC1 and mTORC2, each has a unique role in the pathogenesis and progression of HCC. Despite the limited number of clinical trials related to mTOR, a surprise has been remarkably seen in the development of HCC treatmen via the inhibition of mTOR. However, some details of mTOR signaling seem to be ignored, in particular for cross-talking among various signaling pathways involving mTOR, Wnt, Src-induced and other. Generally, I think that the paper is well-prepared for publication with a scientific merits. A minor revision may be essential for paper publication.

ESPS PEER REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 12934

Title: mTOR Inhibition in Hepatocellular Carcinoma

Reviewer code: 00289669

Science editor: Fang-Fang Ji

Date sent for review: 2014-07-29 19:18

Date reviewed: 2014-08-15 03:51

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input checked="" type="checkbox"/> [Y] Grade A: Excellent	<input type="checkbox"/> [] Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input type="checkbox"/> [] Grade B: Very good	<input checked="" type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> [] Existing	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C: Good	<input type="checkbox"/> [] Grade C: A great deal of language polishing	<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D: Fair	<input type="checkbox"/> [] Grade D: Rejected	<input type="checkbox"/> [] Existing	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E: Poor		<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Major revision

COMMENTS TO AUTHORS

In this review the authors summarize the current progress in the treatment of Hepatocellular carcinoma(HCC)through inhibition of mTOR. They provide detailed information in some key areas associated with the treatment, including the efficacy of mTOR inhibitors in treatment of sorafenib-resistance HCC as well as the associated side effects. Through discussion of several mTOR inhibitors and their effects in clinic setting, the authors suggest that mTOR inhibition, either alone or in combination with other anti-cancer drugs, represents a promising therapeutic option for HCC. This is a very interesting review covering a newly developed area.